Synopsys (SNPS) : Westport Advisers reduced its stake in Synopsys by 4.87% during the most recent quarter end. The investment management company now holds a total of 976,204 shares of Synopsys which is valued at $54,413,611 after selling 50,000 shares in Synopsys , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Synopsys makes up approximately 7.97% of Westport Advisers’s portfolio.
Other Hedge Funds, Including , Susquehanna International Group Llp added SNPS to its portfolio by purchasing 24,485 company shares during the most recent quarter which is valued at $1,364,794. Synopsys makes up approx 0.01% of Susquehanna International Group Llp’s portfolio.Omers Administration Corp boosted its stake in SNPS in the latest quarter, The investment management firm added 30,300 additional shares and now holds a total of 50,400 shares of Synopsys which is valued at $2,809,296. Synopsys makes up approx 0.06% of Omers Administration Corp’s portfolio.State Of Wisconsin Investment Board reduced its stake in SNPS by selling 9,690 shares or 8.78% in the most recent quarter. The Hedge Fund company now holds 100,648 shares of SNPS which is valued at $5,610,120. Synopsys makes up approx 0.02% of State Of Wisconsin Investment Board’s portfolio.Blackrock Fund Advisors boosted its stake in SNPS in the latest quarter, The investment management firm added 638,798 additional shares and now holds a total of 8,114,931 shares of Synopsys which is valued at $452,326,254. Synopsys makes up approx 0.10% of Blackrock Fund Advisors’s portfolio. Smithfield Trust Co sold out all of its stake in SNPS during the most recent quarter. The investment firm sold 11,759 shares of SNPS which is valued $636,867.
Synopsys closed down -0.15 points or -0.25% at $59.14 with 10,46,736 shares getting traded on Thursday. Post opening the session at $58.96, the shares hit an intraday low of $58.66 and an intraday high of $59.41 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Synopsys reported $0.76 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 17, 2016. Analyst had a consensus of $0.74. The company had revenue of $615.20 million for the quarter, compared to analysts expectations of $602.89 million. The company’s revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 EPS.
Many Wall Street Analysts have commented on Synopsys. Company shares were Reiterated by DA Davidson on Aug 18, 2016 to “Buy”, Firm has raised the Price Target to $ 64 from a previous price target of $60 .Company shares were Reiterated by Needham on Aug 18, 2016 to “Buy”, Firm has raised the Price Target to $ 60 from a previous price target of $54 .Company shares were Reiterated by The Benchmark Company on Aug 18, 2016 to “Hold”, Firm has raised the Price Target to $ 60 from a previous price target of $50 .
Synopsys Inc. provides software intellectual property (IP) and services. The Company supplies the electronic design automation (EDA) software that engineers use to design and test integrated circuits also known as chips. It also offers IP products which are pre-designed circuits that engineers use as components of larger chip designs rather than designing those circuits themselves. It provides software and hardware used to develop the electronic systems that incorporate chips and the software that runs on them. It provides technical services to support its solutions and help its customers develop chips and electronic systems. It is also a provider of software tools that developers use to develop software code in a range of industries including electronics financial services energy and industrials. It offers products and services in four categories: core EDA; IP Systems and Software Integrity; Manufacturing Solutions and Professional Services and Other.